- Senior Investigator, Surgery Branch
Dr. Yang graduated from the Massachusetts Institute of Technology with a B.S. in biology. He then completed his M.D. and surgical internship and residency at the University of California, San Diego. In 1984, he came to the Surgery Branch, NCI, as a medical staff fellow. He subsequently became a senior staff fellow, then a senior investigator in 1987. He has been involved in studies of the immune response to tumor-associated antigens and has been a principal investigator of clinical trials in renal cell carcinoma and soft tissue sarcoma.
- (2019). Recognition of human gastrointestinal cancer neoantigens by circulating PD-1(+) lymphocytes. JOURNAL OF CLINICAL INVESTIGATION. 129(11), 4992-5004.
- (2018). The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer. Journal of Thoracic Oncology. 13(6), 792-800.
- (2020). Esomeprazole-induced Stevens-Johnson syndrome in a patient who underwent nivolumab therapy for advanced lung adenocarcinoma. LUNG CANCER. 148, 177-178.
- (2020). Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. NEW ENGLAND JOURNAL OF MEDICINE. 383(10), 931-943.
- (2020). The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation. Therapeutic Advances in Medical Oncology. 12,
- (2020). Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. JOURNAL OF CLINICAL ONCOLOGY. 38(21), 2369-+.